Reading time: 2.5 minutes

Today in Brief

Living longer and healthier – that's medicine's ultimate dream.

What if artificial intelligence could accelerate this quest by revolutionizing cellular reprogramming?

OpenAI just reached a key milestone that could change everything.

Here's what you absolutely need to know.

AI in the Service of Longevity: A Breakthrough That Could Change Everything

Artificial intelligence (AI) continues to surprise, and this time, it's tackling a crucial field: human longevity.

If you're not familiar with the world of AI, here's some context:

AI has already had a massive impact on science, notably with AlphaFold.

A glimpse of the new generation of AlphaFold

Developed by Google, AlphaFold successfully predicted protein structures – a breakthrough that allowed researchers to better understand how human biology works.

Now, OpenAI – the company behind ChatGPT, known for its AI achievements – is entering scientific research with an ambitious project.

Their new AI, called GPT-4b micro, was designed to improve the efficiency of a cellular reprogramming technique.

This technique relies on Yamanaka factors: proteins capable of transforming a normal cell into a stem cell, paving the way for tissue regeneration and cellular rejuvenation.

Shinya Yamanaka, 2012 Nobel Prize winner, identified four genes that can reprogram the genome of body cells – such as skin cells – into embryonic-state cells.

However, this process is slow and inefficient: it takes several weeks to obtain a handful of stem cells, and less than 1% of cells successfully undergo this transformation.

That's where OpenAI comes in: their model generated modifications to optimize these proteins, increasing their efficiency by more than 50 times.

This project emerged from a collaboration with Retro Biosciences, a San Francisco-based startup whose mission is to extend human lifespan by at least 10 years.

And it's no coincidence: Sam Altman, CEO of OpenAI, personally invested $180 million in this company.

In practice, Retro's researchers tested OpenAI's suggestions directly in the lab, and the results were surprisingly effective. The AI proposes modifications that sometimes surpass what humans can conceive on their own.

But this breakthrough also raises questions about how AI can influence science and potential conflicts of interest. After all, Altman is both the founder of OpenAI and the main investor in Retro Biosciences.

What's certain is that this collaboration could mark a turning point in medical research. If AI can make unprecedented scientific discoveries, the entire healthcare sector could benefit.

And you, as a professional?

If AI can improve cellular reprogramming and pave the way for new advances in regenerative medicine, what could the implications be for your field?

Could it accelerate certain treatments, optimize care protocols, or even revolutionize how we approach aging?

Do these advances seem promising to you, or do they raise concerns?

We'd love to hear your thoughts.

TL;DR:

OpenAI developed an AI, GPT-4b micro, capable of optimizing proteins that transform normal cells into stem cells.
This breakthrough could accelerate regenerative medicine and improve the efficiency of cellular rejuvenation techniques.
The project emerged from a collaboration with Retro Biosciences, a longevity-focused startup funded by Sam Altman, CEO of OpenAI.
Initial lab tests show impressive results: Yamanaka factors 50 times more effective.